DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Sang Won | - |
dc.contributor.author | Choi, Donghoon | - |
dc.contributor.author | Heo, MinKyu | - |
dc.contributor.author | Shin, Eui‐Cheol | - |
dc.contributor.author | Park, Su‐Hyung | - |
dc.contributor.author | Kim, So Jeong | - |
dc.contributor.author | Oh, Yeon‐Kyung | - |
dc.contributor.author | Lee, Byung Ha | - |
dc.contributor.author | Yang, Se Hwan | - |
dc.contributor.author | SUNG, YOUNG CHUL | - |
dc.contributor.author | Lee, Howard | - |
dc.date.accessioned | 2021-06-01T04:06:01Z | - |
dc.date.available | 2021-06-01T04:06:01Z | - |
dc.date.created | 2021-02-25 | - |
dc.date.issued | 2020-11 | - |
dc.identifier.issn | 1752-8054 | - |
dc.identifier.uri | https://oasis.postech.ac.kr/handle/2014.oak/105413 | - |
dc.description.abstract | A low lymphocyte count puts immune-compromised patients at risk of mortality. hIL-7-hyFc is a homodimeric interleukin-7 (IL-7), a potent T-cell amplifier, fused to the hybridizing IgD/IgG4 immunoglobulin domain. We performed a randomized, double-blind, placebo-controlled, dose-escalation, phase I study to assess the pharmacokinetic, pharmacodynamic, safety, tolerability, and immunogenicity profiles of hIL-7-hyFc administered s.c. and i.m. to healthy volunteers. Thirty subjects randomly received hIL-7-hyFc or its matching placebo in an 8:2 ratio at 20, 60 mu g/kg s.c., or 60 mu g/kg i.m. The hIL-7-hyFc was slowly absorbed and its terminal half-life was 63.26 hours after i.m. administration. The hIL-7-hyFc increased absolute lymphocyte count, mostly in T-cells, which peaked 3 weeks after administration and then lasted for several additional weeks. The hIL-7-hyFc was well-tolerated after a single s.c. and i.m. administration. Injection site reaction was the most common treatment-emergent adverse event, which resolved spontaneously without treatment. The hIL-7-hyFc can be developed into a beneficial treatment option for patients with compromised T-cell immunity. This trial was registered at as #NCT02860715. | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | Clinical and Translational Science | - |
dc.title | hIL‐7‐hyFc, A Long‐Acting IL‐7, Increased Absolute Lymphocyte Count in Healthy Subjects | - |
dc.type | Article | - |
dc.identifier.doi | 10.1111/cts.12800 | - |
dc.type.rims | ART | - |
dc.identifier.bibliographicCitation | Clinical and Translational Science, v.13, no.6, pp.1161 - 1169 | - |
dc.identifier.wosid | 000534089400001 | - |
dc.citation.endPage | 1169 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1161 | - |
dc.citation.title | Clinical and Translational Science | - |
dc.citation.volume | 13 | - |
dc.contributor.affiliatedAuthor | SUNG, YOUNG CHUL | - |
dc.identifier.scopusid | 2-s2.0-85085026761 | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | RECOMBINANT HUMAN INTERLEUKIN-7 | - |
dc.subject.keywordPlus | CD4+ T-LYMPHOCYTOPENIA | - |
dc.subject.keywordPlus | OPPORTUNISTIC INFECTIONS | - |
dc.subject.keywordPlus | CELL RECOVERY | - |
dc.subject.keywordPlus | LYMPHOPENIA | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | LEUKOENCEPHALOPATHY | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | CLEARANCE | - |
dc.relation.journalWebOfScienceCategory | Medicine, Research & Experimental | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
library@postech.ac.kr Tel: 054-279-2548
Copyrights © by 2017 Pohang University of Science ad Technology All right reserved.